Both cancer cell lines developed resistance to FK866, and interestingly, in both cases, acquired resistance was independent of mutations in NAMPT but rather relied on the activation of alternative metabolic pathways that compensated for low NAD(H) level (Fig. 1a). This evidence concerns the gene NAMPT and cancer.